Investors

Growing Shareholder Value

Press Releases

Abiomed Announces Preliminary Q3 FY 2020 Revenue of $222 Million, up 10% Over Prior Year

Jan 13, 2020
Read More

Abiomed to Present at the 38th Annual J.P. Morgan Healthcare Conference

Dec 30, 2019
Read More

First Patient Enrolls in STEMI DTU Randomized Controlled FDA Trial; Study Aims to Further Demonstrate Impella’s Safety and Effectiveness

Dec 16, 2019
Read More

Abiomed to Present at the 31st Annual Piper Jaffray Healthcare Conference

Nov 27, 2019
Read More

Abiomed Medical Office Completes Review of Observational Analysis of Impella Presented at AHA

Nov 19, 2019
Read More

Clinical Review Demonstrates Cost-Effectiveness of Impella in High-Risk PCI and Cardiogenic Shock

Nov 14, 2019
Read More

First U.S. Patients Treated with Impella 5.5 with SmartAssist, a Minimally Invasive, Forward Flow Heart Pump

Oct 31, 2019
Read More

Abiomed Announces Q2 FY 2020 Revenue of $205 Million and 29.4% Operating Margin

Oct 31, 2019
Read More

FDA Post Approval Study Demonstrates Timely Identification of Right Heart Failure and Early Use of Impella RP Leads to Higher Survival

Oct 25, 2019
Read More

Abiomed Second Quarter Fiscal 2020 Earnings and Conference Call Notification

Oct 10, 2019
Read More
View all